Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2018 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Names New General Counsel

PHOENIX, Oct. 10, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
October 01, 2018 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Signs Definitive License Agreement with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East

PHOENIX, Oct. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
September 27, 2018 18:53 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics to Present at 2018 Cantor Global Healthcare Conference

PHOENIX, Sept. 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
September 24, 2018 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Completes Initial Clinical Study of Dronabinol Inhalation with Innovative Breath-Actuated Inhaler

PHOENIX, Sept. 24, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
September 14, 2018 14:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics to Present at Janney Healthcare Conference

PHOENIX, Sept. 14, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
September 04, 2018 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Expand Collaboration to Include Clinical Study of Cannabidiol in Early Psychosis

PHOENIX, Sept. 04, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
August 30, 2018 06:00 ET | Source: INSYS Therapeutics, Inc.

FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphylaxis

PHOENIX, Aug. 30, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
August 09, 2018 07:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Appoints Elizabeth Bohlen to Board of Directors

PHOENIX, Aug. 09, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
August 08, 2018 16:15 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Reports Second Quarter 2018 Results

PHOENIX, Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids (CBD) and spray...
August 08, 2018 07:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice Investigation

PHOENIX, Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...